Skip to main content

Table 2 Overall and stratified risk estimates of three lipid derivatives for gastric cancer mortality in both derivation and validation groups

From: Prediction of three lipid derivatives for postoperative gastric cancer mortality: the Fujian prospective investigation of cancer (FIESTA) study

Characteristics

Subgroups

Derivation group (n = 1506)

Validation group (n = 1506)

AI

THR

LHR

AI

THR

LHR

Overall

Unadjusted

1.28, 1.22–1.35, < 0.001

1.19, 1,14–1.24, < 0.001

1.24, 1.19–1.30, < 0.001

1.32, 1.23–1.41, < 0.001

1.21, 1.13–1.29, < 0.001

1.29, 1.21–1.38, < 0.001

Overall

Adjusted

1.20, 1.13–1.26, < 0.001

1.17, 1.11–1.24, < 0.001

1.19, 1.13–1.25, < 0.001

1.27, 1.17–1.37, < 0.001

1.16, 1.08–1.24, < 0.001

1.24, 1.15–1.35, < 0.001

Gender

Male

1.27, 1.17–1.38, < 0.001

1.18, 1.11–1.26, < 0.001

1.25, 1.15–1.36, < 0.001

1.30, 1.18–1.43, < 0.001

1.17, 1.08–1.27, < 0.001

1.26, 1.16–1.38, < 0.001

Female

1.16, 1.06–1.26, 0.001

1.17, 1.03–1.33, 0.019

1.19, 1.10–1.29, < 0.001

1.26, 1.06–1.48, 0.012

1.12, 0.97–1.29, 0.136

1.17, 0.96–1.42, 0.118

Smoking

Ever

1.15, 0.90–1.47, 0.133

1.14, 1.05–1.24, 0.011

1.14, 0.90–1.45, 0.270

1.08, 0.90–1.31, 0.397

1.04, 0.87–1.24, 0.649

1.09, 0.90–1.31, 0.381

Never

1.22, 1.13–1.32, < 0.001

1.18, 1.07–1.29, < 0.001

1.23, 1.15–1.34, < 0.001

1.29, 1.18–1.42, < 0.001

1.18, 1.10–1.27, < 0.001

1.29, 1.18–1.40, < 0.001

TNM stage

I-II

1.59, 1.34–1.87, < 0.001

1.29, 1.17–1.42, < 0.001

1.67, 1.38–2.01, < 0.001

1.38, 1.12–1.69, 0.002

1.17, 0.84–1.62, 0.351

1.34, 1.09–1.65, 0.005

III-IV

1.19, 1.13–1.27, < 0.001

1.18, 1.11–1.26, < 0.001

1.17, 1.10–1.23, < 0.001

1.26, 1.16–1.37, < 0.001

1.18, 1.09–1.27, < 0.001

1.24, 1.14–1.35, < 0.001

Lauren’s classification

Intestinal type

1.36, 1.18–1.57, < 0.001

1.27. 1.12–1.44, < 0.001

1.29, 1.11–1.51, 0.001

1.42, 1.20–1.66, < 0.001

1.21, 1.11–1.32, < 0.001

1.34, 1.14–1.58, < 0.001

Diffuse type

1.19, 1.12–1.27, < 0.001

1.16, 1.07–1.26, < 0.001

1.17, 1.10–1.24, 0.001

1.13, 1.04–1.22, 0.003

1.12, 1.05–1.23, 0.003

1.16, 1.06–1.27, 0.001

Tumor embolus

Positive

1.23, 1.13–1.35, < 0.001

1.23, 1.14–1.33, < 0.001

1.28, 1.15–1.42, < 0.001

1.29, 1.15–1.44, < 0.001

1.16, 1.04–1.28, 0.006

1.27, 1.13–1.43, < 0.001

Negative

1.17, 1.09–1.26, < 0.001

1.11, 1.03–1.21, 0.011

1.16, 1.08–1.23, < 0.001

1.25, 1.12–1.40, < 0.001

1.16, 1.06–1.28, 0.002

1.22, 1.09–1.37, 0.001

Obesity

With

1.11, 1.04–1.19, 0.031

1.13, 1.03–1.24, 0.012

1.09, 1.00–1.19, 0.051

1.12, 1.01–1.22, 0.042

1.07, 0.95–1.20, 0.276

1.07, 0.91–1.26, 0.399

Without

1.26, 1.10–1.43, 0.001

1.18, 1.10–1.26, < 0.001

1.24, 1.09–1.40, 0.001

1.31, 1.20–1.43, < 0.001

1.21, 1.11–1.32, < 0.001

1.30, 1.18–1.42, < 0.001

Hypertension

With

1.07, 0.94–1.22, 0.338

1.05, 0.92–1.19, 0.502

1.08, 0.94–1.24, 0.271

1.17, 1.01–1.35, 0.037

1.14, 1.00–1.29, 0.045

1.15, 0.98–1.35, 0.096

Without

1.22, 1.15–1.30, < 0.001

1.21, 1.14–1.28, < 0.001

1.21, 1.14–1.28, < 0.001

1.30, 1.18–1.42, < 0.001

1.16, 1.07–1.26, 0.001

1.27, 1.16–1.39, < 0.001

Diabetes

With

1.13, 1.04–1.22, 0.004

1.08, 1.02–1.16, 0.013

1.14, 1.05–1.25, 0.001

1.17, 1.08–1.28, 0.002

1.07, 0.98–1.16, 0.106

1.18, 1.08–1.29, < 0.001

Without

1.18, 1.07–1.29, 0.001

1.16, 0.98–1.36, 0.080

1.15, 1.06–1.26, 0.001

1.21, 1.08–1.36, < 0.001

1.20, 1.05–1.38, 0.010

1.20, 1.09–1.30, < 0.001

  1. Data are expressed as hazard ratio, 95% confidence interval, P value. Besides unadjusted overall estimates, the other risk estimates were calculated after adjusting for age, gender, smoking, drinking, family cancer history, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, TNM stage, tumor size, Lauren’s classification, number of lymph node metastasis and tumor embolus by removing the characteristic itself in stratified analysis
  2. Abbreviations: AI atherogenic index, THR the triglyceride to high-density lipoprotein cholesterol ratio, LHR the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, TNM tumor-node-metastasis